A retrospective analysis of a cross-sectional, multicenter survey was conducted in United States (US) medical practices to evaluate the concordance between patients with COPD and their physicians on disease-specifi c characteristics. Associations between patient and disease-related characteristics with monotherapy, dual therapy, or triple therapy prescribed as COPD maintenance regimens were also examined. Eligible physicians completed patient record forms (PRFs) for up to 6 consecutive patients with COPD. Patients for whom a PRF was completed were invited to complete a patient self-completion (PSC) survey consisting of questions similar to those on the PRF, as well as several validated measures to assess the impact of COPD on patients' lives. A total of 469 patients completed a PSC that was matched with the PRF completed by their physician, forming the sample for the concordance analysis. Moderate agreement (kappa (κ) = 0.41-0.60) was observed for 79% of measures, with the lowest concordance rating corresponding to hemoptysis (κ = 0.22). There were few differences in demographic or clinical characteristics between patients prescribed monotherapy and dual therapy. Triple therapy rather than monotherapy or dual therapy was more often prescribed for patients with greater frequency of symptoms, negative impact of COPD on daily life and interpersonal relationships, and respiratory impairment based on the most recent FEV 1 . Diverse factors infl uence US physicians' perceptions of disease and treatment choices, including patient symptoms, quality of life, and disease impact. Our results highlight that concordance between physicians and patients regarding symptoms and physical function may contribute to optimal management of COPD.
Introduction
COPD is a complex disorder with wide variability in pulmonary and extrapulmonary manifestations (1) (2) (3) . Th e respiratory, social, and emotional impacts of COPD include pain (4) (5) (6) , dyspnea (4, 5, 7, 8) , fatigue (5, 7, 9) , anxiety (5, 7, 9, 10) , depression (5, 6, 9, 10) , and insomnia (11, 12) . Further studies also confi rm diminished overall physical functioning (6) and quality of life based on validated, disease-specifi c and generic assessment instruments (6, 10, 13, 14) . Notably, 50.8% of adults with COPD require at least one medication to manage the symptoms of COPD, 41 .5% report seeing a physician for COPD symptoms in the past year, and almost 20% require hospital or emergency department care for COPD (15) .
Updated guidance from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends that clinical assessment of patients with
Methods

Research design
Th is study used data from the Adelphi COPD Disease Specifi c Program (DSP), a cross-sectional survey conducted every year that collects information from physicians and their patients with COPD who are presenting for routine care. A complete description of DSP survey methods has previously been published (39) . Th is analysis is based on the COPD DSP that was conducted in the US between September 2012 and November 2012. Physicians and patients provided data in accordance with Health Insurance Portability and Accountability Act (HIPAA) regulations for healthcare market research (40) . Completion of the PSC was voluntary and patients provided consent to use their data for research purposes prior to survey completion.
Physician and patient recruitment criteria
Physicians eligible to complete the survey had completed their medical training in the past 5 to 35 years, were personally responsible for treating patients with COPD, and saw 3 or more patients with COPD per month. Eligibility criteria for patients were age ≥ 40 years, a physician-confi rmed history of smoking (current or ex-smoker), and a physician-confi rmed diagnosis of airfl ow obstruction and COPD, including emphysema and/or chronic bronchitis. Patients with a concomitant diagnosis of asthma were excluded.
Physicians were identifi ed from publically available lists and contacted by telephone to determine if they met the eligibility criteria for the DSP. Eligible physicians completed Patient Record Forms (PRFs) for up to 6 consecutive patients with COPD, regardless of the reason for the appointment. Separately, patients for whom a PRF was completed were invited to complete a voluntary patient self-completion form (PSC), which was independently completed by consenting patients (Figure 1 ). Physicians and patients completed their questionnaires on the same day, which ensured their responses refl ected the same 4-week recall period. Both physicians and patients were assigned unique identification numbers that allowed linkage of patient surveys with the corresponding PRF completed by their physician. Trained local fi eldwork partners collected all data Physicians reported the patient's most recent FEV 1 % predicted, the total number of clinic visits for COPD in the preceding 12 months, overall frequency and healthcare resource utilization for exacerbations of COPD in the past 12 months, and current COPD treatment. Physicians also identifi ed members of the medical team who were responsible for the patient's care and indicated comorbid health conditions. Completion of the PRF took approximately 15 to 20 minutes per patient and physicians were fi nancially compensated for study participation.
Th e wording of questions and responses in the PRF and the PSC were either identical or equivalent, with minor wording changes in the PSC to ensure patient comprehension (eg, hemoptysis on the PRF and coughing up blood on the PSC). Patients also completed several standardized scales that have been validated for use in patients with COPD and other chronic illnesses, including the 8-item Morisky Medication Adherence Scale (MMAS-8), (41) the EuroQol-5 dimensions (EQ-5D) (42) , Work Productivity and Activity Impairment Questionnaire (WPAI) (43) , and the COPD Assessment Test (CAT) (44) . Patients received no compensation for completion of the PSC.
Statistical analysis
Percent responses were calculated for categorical variables and means with standard deviations for continuous variables. Univariate analyses were performed for the concordance and treatment variables, including the chi-square statistic for categorical variables, the Kruskal-Wallis statistic for ordinal variables, and analysis of variance for continuous variables. Th e Bonferroniadjusted t-test, Wilcoxon rank-sum, Fisher's exact test, and chi-square P-values were calculated for pairwise group combinations, where each test was applicable, with corrections for multiple comparisons.
Concordance between physician and patient ratings was calculated for 1) type of COPD symptoms experienced in the last 4 weeks, 2) time of day the patient was most often aff ected by COPD, 3) frequency of COPD symptoms in the last 4 weeks, 4) severity of dyspnea as assessed by the MRC, 5) impact of symptoms on life activities, and 6) severity of symptoms. A weighted kappa statistic was calculated to assess the level of agreement between physicians and their patients with results categorized as (45, 46) : 1) below 0.0 (no agreement); 2) 0.00 to 0.20 (slight agreement); 3) 0.21 to 0.40 (fair agreement); 4) 0.41 to 0.60 (moderate); 5) 0.61 to 0.80 (substantial agreement); and 6) 0.81 to 1.00 (almost perfect agreement) (46) . Th e weighted kappa statistic treated all adjacent categories as equidistant.
Treatment categories included monotherapy (longacting β 2 agonist (LABA) alone, long-acting muscarinic antagonist (LAMA) alone, or inhaled corticosteroid (ICS) alone), dual therapy (free-and fi xed-dose ICS and LABA, ICS and LAMA, or LABA and LAMA), or triple therapy (all formulations of ICS, LABA, and LAMA). Variations in treatment patterns were examined for a number of available patient and disease characteristics that might have infl uenced treatment decisions. Th ese included: 1) medical specialty of the physician currently managing the patient for COPD; 2) number of routine medical appointments in the last 12 months; 3) intervention for COPD exacerbation in the preceding 12 months; 4) patient age; 5) patient gender; 6) smoking status; 7) depression based on physician assessment; and 8) MMAS-8 category. Variations in treatment regimen were also evaluated for the area(s) of impact of COPD relating to 7 activities of daily living; frequency of symptoms, time of day aff ected by symptoms, and type of symptoms in the preceding 4 weeks; most recent FEV 1 % predicted; EQ-5D; WPAI; and CAT.
Instances of missing data for a specifi c variable on the matched PRFs or PSCs resulted in exclusion from analyses that included that specifi c variable. However, matched PRFs and PSCs were included in all analyses of variables for which data were not missing. All statistical analyses were performed with Stata/SE version 12.1 (47) .
Results
Up to 6 PRFs were completed by 149 physicians, including 75 primary care physicians and 74 pulmonologists. Th is resulted in 805 completed PRFs, including 469 linked PSCs and PRFs, which formed the sample for inclusion in the concordance analyses ( Figure 1 ). Clinical and demographic patient characteristics are summarized in Table 1 .
Our concordance analysis revealed moderate agreement (κ = 0.41-0.60) for 79% of measures. Th ere was moderate or substantial agreement for overall perceived severity of symptoms, disease impact, frequency of symptoms in the last 4 weeks, and time of day the patient was aff ected (Table 2) . Notably, substantial agreement (κ = 0.61-0.80) was evident for no symptoms (κ = 0.67), shortness of breath when resting (κ = 0.63), and frequency of symptoms experienced during the daytime (κ = 0.61). Th e lowest concordance rating was evident for hemoptysis (κ = 0.22). Analysis of kappa scores stratifi ed by physician characteristics revealed significantly higher concordance for primary care physicians compared with pulmonologists when rating symptoms of wheezing and getting up and ready for the day.
Signifi cantly higher concordance was evident for hemoptysis in patients with ≥ 3 consultations compared with those who had fewer physician visits in the past 12 months. Th ere were no other signifi cant diff erences in concordance ratings attributable to physician characteristics. In addition, our evaluation of concordance ratings associated with patient demographic or clinical characteristics revealed few signifi cant diff erences, with no consistent pattern in these variations. Notably, there were no systematic patterns to variations in type of treatment (monotherapy, dual therapy, or triple therapy) by concordance ratings.
Type of treatment was not signifi cantly diff erent based on the medical specialty of the managing physician (primary care or pulmonologist; Table 3 ). However, there were signifi cant diff erences in the type of treatment by patient demographic and clinical characteristics (Table 3) . Specifi cally, triple therapy was more likely to be prescribed for patients who had 3 or more routine visits in the past year (73%) compared with 56% of those prescribed monotherapy (P < 0.001). Signifi cantly higher percentages of patients were prescribed monotherapy (75%) or dual therapy (70%) if they required no intervention for COPD exacerbations compared with 51% of those on a triple therapy regimen (P < 0.001 for both comparisons). Th e triple therapy group had a higher proportion of patients 65 years or older compared with the monotherapy and dual therapy groups (Table 3) . Dual therapy rather than monotherapy was more frequently prescribed for patients who experienced bronchospasm and cough in the last 4 weeks. Dual www.tandfonline.com/icop regimens were more likely to be reported than triple therapy for patients with no symptoms in the preceding 4 weeks and those who experienced wheezing. Triple therapy rates were higher compared with monotherapy for all but 2 of the reported symptoms of COPD (Table 4) .
Signifi cant variations in treatment were evident based on the time of day patients were most aff ected by COPD symptoms (Table 5 ). Diff erences in the proportion of patients prescribed the 3 treatment regimens were also associated with the frequency of COPD symptoms (Table 6 ). Triple therapy was more frequently prescribed for patients with scores indicating greater negative impact of COPD on daily activities, mood, interpersonal relationships, leisure time, work, and sleep. Th ere were no signifi cant diff erences in rates of monotherapy and dual therapy for patients based on the impact of COPD on their daily lives (Table 7) . 
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When we examined variations in treatment regimens by the impact of COPD as assessed by FEV 1 , EQ-5D, WPAI, and the CAT, dual therapy was more frequently reported than monotherapy for patients with higher CAT scores. In addition, rates of triple therapy were higher compared with dual therapy regimens for patients with more severe respiratory impairment based on FEV 1 and higher CAT scores. When we compared the monotherapy and triple therapy groups, higher rates of triple therapy were evident for patients with lower FEV 1 scores, lower quality of life, and higher CAT scores, indicating greater impact of COPD on patients' lives (Table 8 ). Physician perceptions of the severity of symptoms were also signifi cantly associated with the choice of treatment, with higher rates of triple therapy prescribed for patients considered to have severe COPD (Figures 2 and 3 ).
Discussion
Our research showed moderate agreement between patients and physicians on the majority of symptoms, with no consistent, signifi cant diff erences attributable to patient demographic or clinical characteristics. Th e areas of highest concordance were evident for disease characteristics that were associated with mild (no symptoms) and severe disease (breathlessness at rest) as well as symptoms most likely to be present at the time of the medical appointment (daytime). It cannot be determined whether this was due to improved detection and/ or dialogue, or lack thereof. Th e fair agreement between patient and physician ratings for hemoptysis and other dimensions with lower levels of concordance may suggest possible areas for improvement in routine discussion and management during clinical visits. *A large number of patients (n = 336) did not complete a PSC and these instruments were also not completed by these patients. Abbreviations: CAT, COPD Assessment Test; EQ-5D, EuroQual-5 dimensions; FEV 1 , forced expiratory volume in 1 second; Mono, monotherapy; WPAI, Work Productivity and Activity Impairment Questionnaire. Signifi cant differences (P ≤ 0.05) shown in bold.
Th e degree of concordance measured in our research was substantially greater than the concordance reported in a previous study for patient and physician ratings of the 4 symptoms that were considered of greatest concern or impact on patients (κ < 0.42) (38) . Physicians selected 4 symptoms from a list of 10 symptoms typically associated with COPD and ranked those they felt were of greatest concern or had the greatest impact on the patient. Patients ranked the 4 symptoms that most aff ected them and evaluated the impact of each of the 10 symptoms on a 5-point Likert-type ordinal scale (38) . Th is was a more subjective and challenging method of concordance measurement compared with that used in our research. Consequently, it may have underestimated concordance. Our method of symptom assessment may provide a more accurate evaluation of concordance because it focuses more on the manifestation of physical symptoms and limitations, which patients and their physicians may be more likely to discuss during a routine visit.
Th e kappa statistic provides no information regarding the dynamics of each responder, just their alignment or lack thereof. Th erefore, it is not clear how physicians or patients were contributing to concordance and discordance. It is also not clear what level of concordance in COPD is required to demonstrate a real improvement in outcomes. Exploration of these issues will require additional research and will provide insights regarding Score: 0 = Only gets breathless after strenuous exercise; 1 = Gets breathless when hurrying on level ground or walking up a slight incline; 2 = On level ground, walks slower than people of the same age because of breathlessness, or has to stop for breath when walking at own pace; 3 = Stops for breath after walking a few meters on level ground; 4 = Is too breathless to leave the house or becomes breathless when getting dressed. contributing factors and strategies for intervention that will improve treatment decision-making and outcomes. Our results did not identify any consistent associations between concordance and treatment regimen based on the variable included in our study and additional research is needed to clarify the impact of improving patientphysician care partnerships and concordance on choice of treatment regimens. Failure of physicians or patients to recognize and discuss symptoms could lead to treatment choices that are not consistent with patients' needs and wishes, and may negatively impact patients' health.
Physicians and patients may benefi t from development of a clear, systematic, and comprehensive process to assess their disease state during appointments, which might overcome recall and communication barriers, facilitate timely exchange of information, and ensure more effi cient treatment, increased patient satisfaction, and enhanced COPD management. Questionnaires such as the CAT provide patients and clinicians with a quick, easy method to assess symptoms, determine a score, and base treatment recommendations on that score (44) . However, we are not aware of research indicating that the use of such standardized assessment tools improves patient-provider communication and concordance. Nor did we identify any research to indicate that the CAT is regularly used in current clinical practice in the US.
Our comparison of patients prescribed monotherapy and dual therapy revealed few diff erences in demographic or clinical attributes. In contrast, many diff erences in demographic and clinical attributes were seen between dual and triple therapy patients, and the greatest number of diff erences was evident between the monotherapy and triple therapy groups. For example, higher disease impact scores in the triple therapy group suggests that certain elements of physicians' perceptions of the impact of COPD on their patients' daily lives, mood, interpersonal relationships, leisure time, work, and sleep were signifi cant factors in treatment decisions. Th ese fi ndings support the premise that treatment decisions, based on this US cohort, are made with a strong emphasis on patient symptoms and functioning, which is consistent with guidance provided by GOLD.
Our analysis did not reveal a consistent pattern of diff erences in concordance associated with physician or patient characteristics, which confi rms the complexity and interrelationship of factors that infl uence management of patients' respiratory health. Similar fi ndings have also been observed in studies of adherence in asthma (48) . Studies designed to support an in-depth analysis of predictors of concordance between patients and physicians and assess the impact of concordance on treatment decisions will be valuable as we strive to improve the care and clinical outcomes of patients with COPD. Not unexpectedly, there was a substantial amount of missing data on FEV 1 , particularly for patients prescribed monotherapy and dual therapy. Previous research by other investigators suggests that a low rate of FEV 1 testing is consistent with real-world practice (48, 49) . Th is implies that treatment decisions may be based on physicians' assessment of patients in the absence of objective measures, such as the FEV 1 . Th is highlights the importance of more holistic patient evaluation, including monitoring respiratory function, symptoms (type, frequency, and severity), and exacerbations, as recommended by the GOLD strategy (17) .
Other limitations merit consideration when evaluating our fi ndings. First, the COPD DSP was not based on a true random sample of physicians or patients. Participation bias of physicians and patients may have infl uenced these results, especially if participants were representative of a sample of patients who were more motivated, more health conscious, or more involved in their condition. We compared patients for whom only a PRF was completed due to patient refusal to participate in the survey (n = 336) and found no signifi cant diff erences in type, severity, impact, or frequency of COPD symptoms, which provides indirect confi rmation s that patients excluded from the concordance analysis were not dissimilar from those who completed a PSC.
Our research design included methods to ensure that physicians and staff were unaware of patient responses within the PSC. However, it was not possible to confi rm that no information exchange occurred between physicians and their patients. Th is could have resulted in infl ation of concordance estimates. Recall bias might also have aff ected the responses of both patients and physicians to the questionnaires, a common limitation of surveys. Additionally, several questions about symptom frequency, type, and severity were not psychometrically developed and validated. However, we also used several instruments that have been validated in patients with COPD, including the CAT, WPAI, MMAS-8, MRC, and the EQ-5D.
Although the number of patient and clinical variables included in this study was extensive, it was not an exhaustive list of all factors that might infl uence treatment decisions. Th e lack of diff erentiation between the monotherapy and dual therapy groups suggests the need for further research to explore and determine factors that may contribute to prescribing decisions associated with each treatment group. It may also be fruitful to identify patient and physician factors that result in escalation of therapy to dual and triple agents.
Real-world surveys such as the DSP have an important role to play in clarifying the dynamics of physicianpatient communication, interactions, and disease management under conditions of actual care. Identifi cation of areas for improvement in the management of patients with COPD is critical given the signifi cant health burden imposed on the US population by COPD (15) , with disease projections indicating that morbidity and mortality rates will continue to rise (51) .
Conclusions
Th ese fi ndings suggest moderate to high concordance between US physician and patient perceptions of type, frequency, and severity of COPD symptoms as well as impact of COPD on patients' daily lives. While relatively few diff erences in demographic or clinical characteristics were associated with rates of monotherapy and dual therapy, we identifi ed many demographic and clinical diff erences between patients prescribed dual or monotherapy compared with triple therapy. Notably, triple therapy was more frequently associated with higher disease impact scores, suggesting that physicians' perception of the impact of COPD on their patients' daily lives was a signifi cant factor in their treatment decisions. Our study suggests that US physicians may be more likely to consider patient symptoms and functioning particularly when making the decision to escalate treatment to triple therapy, which is consistent with the GOLD strategy. However, further study and identifi cation of areas for improvement in the management of patients with COPD remains critical.
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